

Supplementary table 4. Measured LPS bioactivity and the concentrations of LBP, CD14, and CD163.

LPS bioactivity (EU/ml)	ERA (n=30)		CRA (n=28)		All patients (n=58)	
	mean	SD	mean	SD	mean	SD
baseline	0.185	0.086	0.205	0.090	0.195	0.088
follow-up	0.174	0.078	0.215	0.096	0.194	0.088
LBP (ng/ml)						
baseline	8602	3615	8218	4019	8410	3791
follow-up	6138 ***	2866	6409 *	2360	6269 ***	2614
CD14 (ng/ml)						
baseline	2089	694	2139	775	2114	728
follow-up	1998	480	1972	463	1985	468
CD163 (ng/ml)						
baseline	1884	773	1528 †	657	1709	734
follow-up	1325 ***	520	1423	645	1372 ***	580

*** $p \leq 0.001$, ** $p \leq 0.01$, * $p \leq 0.05$ for difference between baseline and follow-up measurements.

† $p \leq 0.05$ for difference between ERA vs CRA.

SD, Standard Deviation; LPS, lipopolysaccharide; ERA, Early Rheumatoid Arthritis; CRA, Chronic rheumatoid arthritis; LBP, LPS-Binding Protein; CD, Cluster of differentiation.